External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience AAN 2023
Roche and Genentech at

AAN 2023

April 22 - April 27
Boston, USA / Virtual (Hybrid)
aan.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
01:00 PM
Duration 12mins S5: Autoimmune Neurology: NMOSD and MG, A Focus On Treatment Trials
Long-term efficacy of satralizumab▼ in adults with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): Results from the roll-over, open-label study SAkuraMoon
A Traboulsee, I Kleiter, J Palace, K Fujihara, A Saiz, I Vodopivec, G Klingelschmitt, C Marcillat, J L. Bennett
Neuroscience | Neuromyelitis Optica

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:48 PM
Duration 12mins S2:Child Neurology and Developmental Neurology
MANOEUVRE study design: A study of GYM329 (RO7204239) in patients with facioscapulohumeral muscular dystrophy (FSHD)
Statland J, Eichinger K, Morrow JM, Tasca G, Vissing J, Dodman A, Jaber B, Kletzl H, McIver T, Scalco RS, Yeung WY, Gaki E, Wagner KR
Neuroscience | facioscapulohumeral muscular dystrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:09 PM
Duration 7mins ES1: Emerging Science 1
Peripheral Blood Gene Expression Transcriptional Profiling Predicts Disease Progression in Primary Progressive Multiple Sclerosis
Gurevich M, Zilkcha-Falb R, Sonis P, Magalashvili D, Menascu S, Dolev M, Achiron A
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:24 PM
Duration 12mins S16: MS Clinical Trials and Therapeutics
Immunological Signatures Associated With Ocrelizumab▼ Treatment in Early RRMS: 12-Month Interim Analysis From the Ocrelizumab▼ Phase IIIb (ENSEMBLE; NCT03085810) Immunological Sub-study
Wirth T, Schulte-Mecklenbeck A, Steinberg OV, Raposo C, Gross CG, Wiendl H, Klotz L
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 12mins Boston Convention and Exhibition Center - 252AB
Enabling subcutaneous dosing of gantenerumab▼ in Alzheimer’s disease
Bittner B, Schwab D, Lott D, Boess F, Kohler R, Portron A, Wojtowicz J, Hofmann C
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:48 PM
Duration 12mins Boston, USA / Virtual (Hybrid)
EXPECTED VS DIAGNOSED RATES OF MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN THE US MEDICARE POPULATION
Mattke S, Jun H, Chen E , Liu Y, Becker A, Wallick C
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 12mins S26: Experimental Therapeutics in Dementia
ALUMNI AD STUDY DESIGN:Evaluation of Subcutaneous Gantenerumab in Historically Underrepresented US Populations With Early Symptomatic Alzheimer’s Disease
Seleri Assuncao S, Brangman S, Henderson J, Parker M, Monroe S, Mintzer J, Wise-Brown A, Grundman M, Smith J, Doody R, Lin H, Assman B, Rippon G
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:48 PM
Duration 12mins Boston Convention and Exhibition Center - 151AB
GRADUATE I and II: Findings of Two Phase III Randomized Placebo-controlled Studies Assessing the Efficacy and Safety of Subcutaneous Gantenerumab▼ in Early Alzheimer’s Disease (AD)
Smith J, Donohue MC, Gruendl E, Grimmer T, Perry RJ, Black SE, Salloway S, Lyons M, Rutten-Jacobs L, Bittner T, Blennow K, Pelentrides C, Barkhof F, Tonietto M, Baudler-Klein M, Fontoura P, Doody RS
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:30 PM
Duration 12mins S31: MS Clinical Decision Making and Special Populations
An Interim Analysis of Efficacy and Safety Data in Black and Hispanic Patients With Multiple Sclerosis Receiving Ocrelizumab▼ Treatment in the CHIMES Trial
Bernitsas E, Reder AT, Chinea A, Herrman C, O’Brien BC, Sater RA, Amezcua L, Williams MJ, Wu GF, Vartanian T, Pei J, Acosta J, Monson NL
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:36 PM
Duration 12mins S34:Child Neurology and Developmental Neurology
SUNFISH Parts 1 and 2: 4-year efficacy and safety of risdiplam▼ in Types 2 and 3 spinal muscular atrophy (SMA)
L Servais, M Oskoui, J W Day, N Deconinck, E S Mazzone, A Nascimento, K Saito, C Vuillerot, G Baranello, O Boespflug-Tanguy, N Goemans, J Kirschner, A Kostera-Pruszczyk, J Braid, G Papp, K Gorni, C Martin, R S Scalco, W Y Yeung, E Mercuri
Neuroscience | Spinal Muscular Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:12 PM
Duration 12mins S46: MS Therapeutics and Clinical Decision Making
Long-term Treatment with First-Line Ocrelizumab▼ in Patients with Early RMS: 9-Year Follow-Up Data From the OPERA Trial
Cerqueira J, Berthele A, Cree BAC, Filippi M, Pardo G, Pearson O, Traboulsee A, Ziemssen T, Vollmer T, Bernasconi C, Mandel C, Kulyk I, Chognot C, Schneble H-M, Prajapati K, Havrdova EK
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:24 PM
Duration 12mins S46: MS Therapeutics and Clinical Decision Making
Delayed Signs of Early Disability Progression After 8.5 Years of Ocrelizumab▼ Treatment in Patients With Relapsing Multiple Sclerosis
Weber MS, Kappos L, Hauser SL, Schneble HM, Wang Q, Giovannoni G
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:36 PM
Duration 12mins S46: MS Therapeutics and Clinical Decision Making
Low Disease Activity Over 4 Years of Ocrelizumab▼ Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE Study
Bermel R, Hartung HP, Brochet B, Benedict R, Berger T, Carroll W, Vollmer T, Holmøy T, Karabudak R, Killestein J, Nos C, Patti F, Perrin Ross A, Vanopdenbosch L, Wuerfel J, Kuenzel T, Kadner K, Kulyk I, Freedman M
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:54 PM
Duration 12mins Session S48: Therapeutics for Muscle Disease
One-year Data from ENDEAVOR, a Phase 1b Trial of Delandistrogene Moxeparvovec (SRP-9001) in Patients with Duchenne Muscular Dystrophy (DMD)
Craig Zaidman, Crystal Proud, Craig McDonald, Stefanie Mason, Maitea Guridi, Shufang Wang, Carol Reid, Eddie Darton, Christoph Wandel, Sarah Lewis, Jyoti Malhotra, Danielle A. Griffin, Rachael A. Potter, Louise R. Rodino-Klapac, Jerry R. Mendell
Neuroscience | Duchenne Muscular Dystrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:06 PM
Duration 12mins Session S48: Therapeutics for Muscle Disease
A Phase 2 Clinical Trial Evaluating the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Patients with Duchenne Muscular Dystrophy (DMD)
Perry B. Shieh, Mendell JR, Sahenk Z, Lehman KJ, Lowes LP, Reash NF, Megan A. Iammarino, Lindsay N. Alfano, Brenna Sabo, Jeremy D. Woods, Christy L. Skura, Howard C. Mao, Loretta A. Staudt, Rachael A. Potter, Danielle A. Griffin, Sarah Lewis, Larry Hu, Teji Singh, Louise R. Rodino-Klapac
Neuroscience | Duchenne Muscular Dystrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:18 PM
Duration 12mins S49: General Neurology
Telemedicine Use Before and During the COVID-19 Pandemic Among People With Neurological Disorders: a Cross-Sectional Study Using US Commercial Claims Data
AM Patel, R Schuldt, DM Boudreau, N Win, BR Cobb, M McGinley.
Neuroscience | Neurodegenerative Diseases

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:30 PM
Duration 12mins Session S48: Therapeutics for Muscle Disease
Integrated Analyses of Data from Clinical Trials of Delandistrogene Moxeparvovec (SRP-9001) in Duchenne Muscular Dystrophy (DMD)
Craig Zaidman, Perry B. Shieh, Crystal Proud, Craig McDonald, John W. Day, Stefanie Mason, Maitea Guridi, Lixin Han, Lixi Yu, Carol Reid, Eddie Darton, Christoph Wandel, James Richardson, Jyoti Malhotra, Teji Singh, Louise R. Rodino-Klapac, Jerry R. Mendell
Neuroscience | Duchenne Muscular Dystrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.